|
1
|
Walboomers JM, Jacobs MV, Manos MM, et al:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999.
|
|
2
|
Khan MJ, Castle PE, Lorincz AT, et al: The
elevated 10-year risk of cervical precancer and cancer in women
with human papillomavirus (HPV) type 16 or 18 and the possible
utility of type-specific HPV testing in clinical practice. J Natl
Cancer Inst. 97:1072–1079. 2005.
|
|
3
|
Li N, Franceschi S, Howell-Jones R,
Snijders PJ and Clifford GM: Human papillomavirus type distribution
in 30,848 invasive cervical cancers worldwide: Variation by
geographical region, histological type and year of publication. Int
J Cancer. 128:927–935. 2011.
|
|
4
|
Bouvard V, Baan R, Straif K, et al: A
review of human carcinogens - Part B: biological agents. Lancet
Oncol. 10:321–322. 2009.
|
|
5
|
de Sanjose S, Quint WG, Alemany L, et al:
Human papillomavirus genotype attribution in invasive cervical
cancer: a retrospective cross-sectional worldwide study. Lancet
Oncol. 11:1048–1056. 2010.
|
|
6
|
Smith JS, Lindsay L, Hoots B, et al: Human
papillomavirus type distribution in invasive cervical cancer and
high-grade cervical lesions: a meta-analysis update. Int J Cancer.
121:621–632. 2007.
|
|
7
|
Ivansson EL, Gustavsson IM, Wilander E,
Magnusson PK and Gyllensten UB: Temporal trends over 3 decades and
intrafamilial clustering of HPV types in Swedish patients with
cervical cancer in situ. Int J Cancer. 125:2930–2935.
2009.
|
|
8
|
The National Board of Health and Welfare.
Cancer Incidence in Sweden 2008. The National Board of Health and
Welfare; Stockholm, Sweden: 2009, (In Swedish). http://www.socialstyrelsen.se/publikationer2009/2009-12-1.
Accessed December 1, 2009
|
|
9
|
Official Statistics of Sweden
Statistics-Health and Medical Care. Cancer Incidence in Sweden
2009. The National Board of Health and Welfare Centre for
Epidemiology; Stockholm, Sweden: 2010, (In Swedish). http://www.socialstyrelsen.se/publikationer2010/2010-12-17.
Accessed December 17, 2010
|
|
10
|
Official Statistics of Sweden
Statistics-Health and Medical Care. Causes of Death in Sweden 2009.
The National Board of Health and Welfare Centre for Epidemiology;
Stockholm, Sweden: 2011, (In Swedish). http://www.socialstyrelsen.se/publikationer2011/2011-3-22.
Accessed March 22, 2011
|
|
11
|
Gyllensten U, Lindell M, Gustafsson I and
Wilander E: HPV test shows low sensitivity of Pap screen in older
women. Lancet Oncol. 11:509–510. 2010.
|
|
12
|
Gyllensten U, Gustavsson I, Lindell M and
Wilander E: Primary high-risk HPV screening for cervical cancer in
post-menopausal women. Gynecol Oncol. 125:343–345. 2012.
|
|
13
|
Gustavsson I, Juko-Pecirep I, Backlund I,
Wilander E and Gyllensten U: Comparison between the Hybrid Capture
2 and the hpVIR real-time PCR for detection of human papillomavirus
in women with ASCUS or low grade dysplasia. J Clin Virol. 45:85–89.
2009.
|
|
14
|
Gustavsson I, Lindell M, Wilander E,
Strand A and Gyllensten U: Use of FTA card for dry collection,
transportation and storage of cervical cell specimen to detect
high-risk HPV. J Clin Virol. 46:112–116. 2009.
|
|
15
|
de Sanjosé S, Diaz M, Castellsagué X, et
al: Worldwide prevalence and genotype distribution of cervical
human papillomavirus DNA in women with normal cytology: a
meta-analysis. Lancet Infect Dis. 7:453–459. 2007.
|
|
16
|
Bergstrom R, Sparen P and Adami HO: Trends
in cancer of the cervix uteri in Sweden following cytological
screening. Br J Cancer. 81:159–166. 1999.
|
|
17
|
Gunnell AS, Ylitalo N, Sandin S, et al: A
longitudinal Swedish study on screening for squamous cell carcinoma
and adenocarcinoma: evidence of effectiveness and overtreatment.
Cancer Epidemiol Biomarkers Prev. 16:2641–2648. 2007.
|
|
18
|
Gustafsson L, Sparen P, Gustafsson M, et
al: Low efficiency of cytologic screening for cancer in situ
of the cervix in older women. Int J Cancer. 63:804–809. 1995.
|
|
19
|
Lindell M, Sanner K, Wikstrom I and
Wilander E: Self-sampling of vaginal fluid and high-risk human
papillomavirus testing in women aged 50 years or older not
attending Papanicolaou smear screening. BJOG. 119:245–248.
2012.
|
|
20
|
Tanaka H, Karube A, Tanaka T and Nakagomi
O: Much higher risk of premalignant and malignant cervical diseases
in younger women positive for HPV16 than in older women positive
for HPV16. Microbiol Immunol. 45:323–326. 2001.
|
|
21
|
Zehbe I, Wilander E, Delius H and
Tommasino M: Human papillomavirus 16 E6 variants are more prevalent
in invasive cervical carcinoma than the prototype. Cancer Res.
58:829–833. 1998.
|
|
22
|
Richard C, Lanner C, Naryzhny SN, et al:
The immortalizing and transforming ability of two common human
papillomavirus 16 E6 variants with different prevalences in
cervical cancer. Oncogene. 29:3435–3445. 2010.
|
|
23
|
Ronco G, Giorgi-Rossi P, Carozzi F, et al:
Efficacy of human papillomavirus testing for the detection of
invasive cervical cancers and cervical intraepithelial neoplasia: a
randomised controlled trial. Lancet Oncol. 11:249–257. 2010.
|
|
24
|
Leinonen M, Nieminen P, Kotaniemi-Talonen
L, et al: Age-specific evaluation of primary human papillomavirus
screening vs conventional cytology in a randomized setting. J Natl
Cancer Inst. 101:1612–1623. 2009.
|
|
25
|
Katki HA, Kinney WK, Fetterman B, et al:
Cervical cancer risk for women undergoing concurrent testing for
human papillomavirus and cervical cytology: a population-based
study in routine clinical practice. Lancet Oncol. 12:663–672.
2011.
|
